 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

---
- 'The Schall Law Firm, a national shareholder rights litigation firm, announces that
  it is investigating claims on behalf of investors in Viatris Inc. (Viatris or the
  Company) (NASDAQ: VTRS) who formerly held shares of Mylan Inc. (NASDAQ: MYL) for
  violations of the securities laws. If you are a...'


INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Viatris Inc. and Encourages Investors who Formerly Held Shares of Mylan Inc. (MYL) to Contact the Firm

---
- 'Viatris Inc. on Tuesday announced that a class action lawsuit filed almost four
  years ago against predecessor company Mylan NV regarding the pricing and marketing
  of emergency allergy medication EpiPen has been dismissed by a Kansas court. Viatris
  (NASDAQ: VTRS) said in a release that the U.S.'


Court dismisses class action suit against Mylan regarding EpiPen

---
- 'Viatris is moving ahead with the closure of its predecessor Mylan''s original manufacturing
  plant in Morgantown, West Virginia, next month. The Canonsburg-based Viatris (Nasdaq:
  VTRS) announced in December after Mylan''s merger with Upjohn that it would be closing
  more than a dozen facilities worldwide.'


Viatris sets next month for closing of Morgantown drug manufacturing plant

---
- 'International pharmaceutical giant Sanofi is back in court against Mylan and its
  successor company, Viatris, with an appeal of a December summary ruling in a lawsuit
  Sanofi filed against Mylan''s EpiPen. Sanofi-Aventis US, a division of Sanofi (Nasdaq:
  SNY) last month filed a brief with the 10th Circuit Court of Appeals, contesting
  the ruling in the case Sanofi first filed in August 2017 in the U.S.'


Sanofi files appeal in case against Mylan over Epipen

---
- Sanofi looks to take Mylan to court, again, over EpiPen antitrust allegations
- fkansteiner
- Wed, 06/02/2021 - 11:24...


Sanofi looks to take Mylan to court, again, over EpiPen antitrust allegations

---
- As former Officer Derek Chauvin stands trial in George Floyds death, a central question
  is whether he followed the Minneapolis Police Departments guidelines on the use
  of force and used that force reasonably. The departments longest-tenured officer
  sharply criticized Chauvin&#...


EXPLAINER: Analyzing use of force by police officers

---
- Jurors on Wednesday saw Minneapolis police officers body camera footage showing
  how an initial confrontation over an alleged misdemeanor last year spiraled into
  George Floyd begging for his life underneath the knee of a police officer as two
  other officers held him down. Police departments ...


EXPLAINER: Use-of-force experts evaluate Floyd arrest

---
- As attorneys argued over whether to allow evidence from George Floyds 2019 arrest
  at the trial of a former police officer charged in his death in 2020, Judge Peter
  Cahill wanted to know the relevance of Floyds behavior a year before he died. Werent
  Derek Chauvin and other officers duty...


EXPLAINER: How is officer's duty relevant to Floyd case?

---
- Court of Appeal rejects Gilead claim that Truvada is protected against Teva and
  Mylan alternative...


Pharma firm loses patent suit to stop generic HIV drug

---
- 'Teva, Mylan and fellow valsartan makers have to face consumer fraud claims: judge'
- fkansteiner
- Mon, 02/01/2021 - 09:53...


Teva, Mylan and fellow valsartan makers have to face consumer fraud claims: judge

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Watchers	5,834
52-Wk Low	$8.45
52-Wk High	$12.40

Market Cap	$11.5B
Volume (M)	262,401.00
52-Wk High	$12.40
52-Wk Low	$8.45

MYL Mylan, Inc.

About

Feed

News

Fundamentals